Antineoplastic combinations
Liposomal daunorubicin with cytarabine
(Danuorubicin 44mg / Cytarabine 100mg)
- Vyxeos liposomal powder for concentrate for solution for infusion vials 44mg/100mg
Notes
- NICE TA552: Liposomal cytarabine–daunorubicin (Vyxeos) is recommended, within its marketing authorisation, as an option for untreated therapy-related acute myeloid leukaemia or acute myeloid leukaemia with myelodysplasia-related changes in adults (December 2018)
- It is recommended only if the company provides it according to the commercial arrangement.
- MHRA Drug Safety Update (July 2020): Liposomal and lipid-complex formulations: name change to reduce medication errors.
Trifluridine with tipiracil
- Tablets trifluridine 15mg/tipiracil 6.14mg, trifluridine 20mg/tipiracil 8.19mg
Notes
- NICE TA405: Trifluridine–tipiracil (Lonsurf) is recommended as an option for treating metastatic colorectal cancer (August 2016), that is:
- in adults who have had previous treatment with available therapies including fluoropyrimidine-, oxaliplatin- or irinotecan-based chemotherapies, anti-vascular endothelial growth factor (VEGF) agents and anti-epidermal growth factor receptor (EGFR) agents, or when these therapies are not suitable, and
- only when the company provides trifluridine–tipiracil with the discount agreed in the patient access scheme.
- NICE TA852: Trifluridine–tipiracil (Lonsurf) is recommended, within its marketing authorisation, as an option for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma in adults who have had 2 or more treatment regimes, only if the company provides it according to the commercial arrangement (December 2022).